Alex Guevara, DO
Family Medicine · Fort Worth, TXNPI 1699768481
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,486 of the $15,121 with a category attached, or 89.2%. It is spread thinly across 51 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 743 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$1K
- Amgen$1K
- Gilead$927
- Lilly USA, LLC$897
- Bayer$772
- plus $7K from 45 others
Across 217 payments — averaging $9848.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.5M
- Regeneron$365K
- Kowa Research Institute, Inc.$136K
- Sanofi US Services Inc.$96K
- AstraZeneca$61K
- Novo Nordisk AS$19K
- plus $3K from 1 others
What the payments were for
- Consulting fees$1,0247%
- Travel & lodging$4923%
- Food & beverage$13,48689%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,121 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 26 | $31,257 |
| MounjaroTirzepatide | 24 | $30,944 |
| OzempicSemaglutide | 23 | $25,354 |
| JardianceEmpagliflozin | 18 | $17,912 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $11,464 |
| VascepaIcosapent Ethyl | 26 | $9,625 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $8,506 |
| Rosuvastatin Calcium | 91 | $1,508 |
| SynthroidLevothyroxine Sodium | 13 | $875 |
| Ezetimibe | 45 | $685 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $587 |
| Amlodipine Besylate | 89 | $585 |
| Atorvastatin Calcium | 45 | $492 |
| Omeprazole | 31 | $441 |
| Losartan Potassium | 30 | $418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,580 | $31,25726 claims |
| Lilly USA, LLCMounjaro | $897 | $30,94424 claims |
| Novo NordiskOzempic | $1,399 | $25,35423 claims |
| Boehringer IngelheimJardiance | $767 | $17,91218 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $397 | $8,50616 claims |
| AbbVieSynthroid | $260 | $87513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- Robert CampbellFort Worth$318K
- Kenton MurthyFort Worth$40K
- Peter DamicoFort Worth$37K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.